New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Cellectar Biosciences, Inc.

Contributing Author

Recent Articles by Cellectar Biosciences, Inc.

Sep-30	Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer CLRB GlobeNewswire
Sep-24	Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) CLRB GlobeNewswire
Sep-11	Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 CLRB GlobeNewswire
Sep-09	Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit CLRB GlobeNewswire
Sep-05	Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September CLRB GlobeNewswire
Sep-03	Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research CLRB GlobeNewswire
Aug-27	Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer CLRB GlobeNewswire
Aug-14	Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update CLRB GlobeNewswire
Aug-07	Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 CLRB GlobeNewswire
Jul-02	Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option CLRB GlobeNewswire
Jul-01	Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering CLRB GlobeNewswire
Jun-26	Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement CLRB GlobeNewswire
Jun-24	Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) CLRB GlobeNewswire
Jun-18	Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split CLRB GlobeNewswire
Jun-11	Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma CLRB GlobeNewswire
Jun-05	Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules CLRB GlobeNewswire
Jun-04	Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) CLRB GlobeNewswire
May-13	Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update CLRB GlobeNewswire
May-07	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 CLRB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.